Italy· 029103013
INIBACE PLUS*14 cpr rivestite 5 mg + 12,5 mg
A medicinal product containing cilazapril/idroclorotiazide, registered in Italy by CHEPLAPHARM ARZNEIMITTEL GMBH, on the national reimbursement list.
Checked against the register on
Informational only — not a medical device.
The record
At a glance
- Active substance
- Cilazapril/idroclorotiazide
- Manufacturer
- CHEPLAPHARM ARZNEIMITTEL GMBH
- Country
- Italy (IT)
- ATC code
- —
- Reimbursed
- Yes
- Last checked
- June 4, 2026
Packs & prices · 1
1 priced- aic029103013INIBACE PLUS*14 cpr rivestite 5 mg + 12,5 mgEUR 8.63
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cdf6c16b-8b34-4b55-bb22-a9b3b490d0fc GET /v1/drugs/cdf6c16b-8b34-4b55-bb22-a9b3b490d0fc?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"price": 8.63,
"source": "aifa",
"currency": "EUR",
"strength": "CILAZAPRIL+IDROCLOROTIAZIDE 5+12,5MG 14 UNITA' USO ORALE",
"substance": "Cilazapril/idroclorotiazide",
"equivalence_group": "J7A",
"transparency_flag": null
}See everything about cilazapril/idroclorotiazide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.